chrisvoncsefalvay/vaers-outcomes huggingface dataset:
booster dose was much less severe; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION COMPLICATION (booster dose was much less severe) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (booster dose was much less severe). At the time of the report, VACCINATION COMPLICATION (booster dose was much less severe) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant drug was reported. The patient received first booster. Reporter called to report about her daughter's reaction to Moderna doses. No treatment drug was reported.   This case was linked to MOD-2021-079311, MOD-2021-079320.
This spontaneous report as received from a certified medical assistant (C.M.A.) refers to her 23 month old daughter. On 23-JUL-2014, the patient was vaccinated with a first dose of VAQTA (0.5 ml, intramuscular in the left arm, lot# and expiration date were not reported). On 22-JAN-2015, the patient was vaccinated with a second dose of VAQTA (0.5 ml, intramuscular in the left arm, lot# and expiration date were not reported). The time between the first and the second vaccination was considered to be too short (also reported as one day shy of 6 months). No adverse effects were reported. No product quality complaint (PQC) was involved. Additional information is not expected, because a physician did not wish to be contacted.
I was given Paxlovid the first day of treatment. The only reason I took a COVID-19 test was because I had a mild fever on 02/01/2023. I had been feeling off that day, and the test came back positive. I felt almost asymptomatic. After the first day, I had a slight fever and light cough. After my course of taking Paxlovid, I tested negative on 02/05/2023. I still had a light cough and congestion and tested positive again on 02/12/2023 which I figured was rebound COVID-19. That lasted until 02/23/2023 when I finally tested negative again. I still had a residual cough that caused a low-grade fever and body chills for about 5 or 6 days. I decided to go to the emergency room on 02/28/2023 because of the residual symptoms where they performed a chest x-ray and confirmed I had pneumonia; they sent me home with antibiotics. I received six shots of Evusheld during the course process of recovery from COVID-19.  I felt crappy and went back to the emergency room where they confirmed I recovered from pneumonia but lingering symptoms that cleared up within some days following.
lower back pain; walking on the slower pace; her arm was not husting anymore; This is a spontaneous report from a contactable consumer (patient). A 66-years-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9267; Expiration Date: 31May2021), via an unspecified route of administration on 11Feb2021 as 1st dose, single for COVID-19 immunisation.  Medical history included stenosis and stiffness in the back, both ongoing. The patient's concomitant medications were not reported.  The patient experienced lower back pain on an unspecified date in Feb2021. Patient reported that she had stenosis but had different kind of stiffness in the back. She was walking on the slower pace; her arm was not husting anymore. The outcome of events was unknown.    Follow-up attempts are completed. No further information is expected.
On Sunday night, 04/11/2021 around 7:00pm, patient stated she started getting sick to her stomach.  She complained of headaches and  fatigue. At midnight she vomited, couldn't lay down and symptoms lasted all night.  She complained of back pain too.  she noticed blood in her urine with a clot of blood in it and had shortness of breath.    She vomited twice.  In contact by phone with her daughter at the time.   Patient refused to go the the emergency room or call her physician.  She has a cardiologist who is her primary care physician.
This spontaneous report as received from a nurse refers to a 3 year old patient of unknown gender. On an unknown date the patient was vaccinated with the first dose of M-M-R II, (dose, route, lot# and expiration date unknown) at age three years. No adverse effects were noted. Action taken with M-M-R II was not applicable. The outcome of event was unknown. Additional information has been requested.
Lack of appetite; persistent fever, wake and its over 102; Chills; Fatigue; This is a spontaneous report from a contactable consumer (patient). A 93-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9264) as a single dose via unspecified route on 05Feb2021 at 11:00 AM at the age of 93-year-old for COVID-19 immunisation. Medical history included fibromyalgia, HTN (hypertension), COPD (Chronic obstructive pulmonary disease), hypothyroid, hypercholesterolemia and dairy allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. It was reported that the patient did not received any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included thyroid, carvedilol, amlodipine, torsemide, lomustine (PRAVA) taken within two weeks of vaccination. On 06Feb2021, the patient experienced persistent fever, wake and its over 102. The patient had taken tylenol at 8am, 3pm and 9pm, Ibuprofen 10am and 5pm for the event. The lowest temperature goes with 3 weeks of this routine is 98.4, if patient missed or was late on any of the medications listed, fever jumped right into 102. The patient also had chills, fatigue and lack of appetite. The patient underwent lab test on 06Mar2021 which included COVID-19 blood test which was negative. The outcome of events was not recovered.   No follow-up attempts are needed. No further information is expected.
woke up morning after immunization with swollen and warm red upper arm. patient complained of sweats. patient went to doctor and was told she had an infection. she received a prescription for doxycycline.
shingles; This spontaneous report was received on 09-DEC-2019, from a lawyer regarding a case in litigation and refers to a female patient (pt) of an unknown age. The pt's medical history, concurrent conditions and concomitant medications were not reported. On or around 27-FEB-2014, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (exact dose, site and route of administration, lot# and expiration date were not reported) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX), the pt suffered a bad case of shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccine, the pt's symptoms had resulted in physical limitations not present prior to using the vaccine. The pt also experienced mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the pt sustained severe and permanent personal injuries. Further, as a tragic consequence of the vaccine, the pt suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result, she had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of shingles was reported as not recovered. The relatedness between the event and zoster vaccine live (ZOSTAVAX) was related.  The event of shingles was considered to be disabling by the reporter.
Information has been received from an office manager concerning multiple unspecified patients of unknown age and gender. The patients' concurrent conditions, medical histories and concomitant therapies were not provided. On unknown dates, the patients were vaccinated with improperly PNEUMOVAX 23 injection (lot # L019836, expiration date 24-MAR-2017; strength dose, frequency and route were unknown), which was exposed to temperature excursion of 31.1 degrees Fahrenheit for 2 hours (1 cycle). There were no previous temperature excursion. It was unknown if data logger involved. No adverse effects were reported. No product quality complaint (PQC) was involved. Additional information has been requested.
Had blister area just below injection site where DTaP was given in left deltoid on 07/19/07, blister appeared later that night temp of 102.9.  Took to ambulatory care center and had blood drawn, diagnosed with a skin infection, treated with Keflex, silvadene cream, and acyclovir.
Arm pain was pretty severe - reminded me like what you get from a tetanus shot and a little burn-y. It did clear up with Advil. Arm pain was gone by the 7th. On Wednesday, the 6th, I was tired and didn't have an appetite. Regular foods that I would like to eat didn't sound good. Would feel hunger pains but didn't know what to eat. I had abdominal pain - on lower right of abdomin. On Friday, I went to urgent care - when Dr pressed one area he said it was my ovary. My mom passed away from Ovarian cancer so dr ordered Pelvic ultrasound.  Loss of appetite was starting to get better on Sunday. On Tuesday or Wednesday it was back to normal (appetite).
Injection site, (+) erythema (9 x 11.5 cm), tenderness.
A report has been received from a Health Professional concerning a 3 year old, Female subject, who had been receiving Nasal FLUMIST. FLUMIST started on 18-Dec-2012. The patient experienced EXPIRED FLUMIST GIVEN which started on 18-Dec-2012. The outcome of the event of EXPIRED FLUMIST GIVEN is unknown. The report was considered to be non-serious by the company physician. Follow up of insignificant information received on 08-Apr-2013. The patient did not have any late occurring adverse events. Another immunization was offered one month later, but was declined. Narrative was updated.
I received the booster shot in my right arm and 2 days later a large bruise appeared on the opposite (left) arm.
Pt was given immunization at 11:15 by 11:25 pt was fainting. Pt. reaction: mild fainting episode with mild swaying, father grabs pt. Pt was placed supine on floor. Pt was loss of awareness or significant bradycardia or hypotension. Pt was observed in office 30 min w/ BP taken several times, discharge B/P=112/20.
Patient reported that the night that the vaccine was administered he had tingling in his lips and and tongue, and his heart was racing.
Information has been received from a physician concerning a 60 day old female infant with umbilical hernia and a history of breathing difficult, heart rate irregular and premature baby who on 24-Nov-2008 was vaccinated with RECOMBIVAX HB. Concomitant therapy included vaccination with RECOMBIVAX HB (MSD) on 29-Jan-2009 and 26-Mar-2009. On 22-Jan-2009, the patient was seen in the physicians office because she experienced "gasps for air", difficulty swallowing and was constipated. It was reported that the patient had "intermittent problems breathing, making a noise breathing in/out all of the time. When she wakes up in the morning and into night occurring when she was awake and asleep." The pain was to monitor the patient for now, if the breathing problem progressed to contact the physician. The patient was to be recheck in one week. On 29-Jan-2009, at the patient's 2 month check-up, it was reported that the patient experienced diarrhea. On 18-Feb-2009, the patient experienced upper respiratory tract infection. It was reported that the patient was sleeping a lot the past 3 days. The patient's mother was concerned as the patient only wakes to eat and her appetite was decreased. It was also reported that the patient has been congested for the past 2 weeks. Laboratory/diagnostic tests performed at this time showed pulse oximetry at 100%, glucose at 84 and metabolic panel was normal. Instructions were provided for administration of saline nasal spray as treatment. On 26-Mar-2009, the patient experienced labial fusion. The patient was treated with PREMARIN CREAM), three times a day for 7 days, two times a day for 3 days, once a day for 2 days and then Vaseline daily. A follow-up appointment was recommended for 2 months. At the time of reporting, the outcome and causality for the events was unknown. Additional information has been requested.
Information has been received from a 65 year old female patient with an allergy to horse serum and with no relevant medical history who on 08-JUL-2010 was vaccinated IM with the first dose of PNEUMOVAX 23 in her left upper arm. Concomitant therapy included trazodone HCl, EVISTA and FEMHRT. The patient reported that she went to the physician for a routine physical. As a part of the physical because of her age, 65, she received the vaccination. She had been fasting for 12 hours prior to her visit. After her vaccine injection on 08-JUL-2010, while making her way out of the office, she took a sip of water and began to feel stomach cramps and a headache. She then re-entered the office and was brought to an exam room and upon entering the room began experiencing severe back spasms that were very painful. She was placed prone onto an exam table and given a back massage to alleviate the spasms. They subsided after 20 minutes. The physician was perplexed as to why she was experiencing these symptoms. The patient then left the office and while driving home she started to experience severe pelvic pain along with leg, hand and foot pain. She felt very sleepy upon arriving home and went in to lay down, but then started experiencing severe chills that lasted for approximately 2 hours. When the chills finally passed she was symptom free and was fully recovered on 09-JUL-2010. Stomach cramps, headache, severe back spasms, severe pelvic pain, leg, hand and foot pain, felt very sleepy and severe chills were considered to be disabling. Additional information has been requested.
Fever up to 101.6  Chills Body aches  Headache  Fatigue
Most extreme chills Fever 100 F Headache Neck ache Body aches Fatigue All lasted until about 6pm and then patient was fine. Got Covid at work in March 2020
Mom knowingly misrepresented child's DOB as 08/10/2008 (12yrs) instead of actual birthday of 08/10/2009 (11yrs). Child's real birthday was discovered upon billing the claim through insurance. Child's DOB was verbally confirmed as 12 years old by mother at check in and by the child right before administration. No adverse reaction was reported yet.
Patient noticed red, slightly raised area 2.5" diameter approximately 24 hours after the vaccine injection. It is less red, but slightly itchy and still 2.5" in diameter after six weeks.
Patient reported flu like symptoms starting two hours after receiving the vaccination. Symptoms included: red, sore arm; fever (temp was not taken by patient); body aches; chills; sweating; nausea. The next morning of 4/24/18 pt was feeling better but not great. On 4/25/18 she felt back to normal.
22 patients vaccinated using old vial from 03/08/2021; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (22 patients vaccinated using old vial from 03/08/2021) in a 54-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (22 patients vaccinated using old vial from 03/08/2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (22 patients vaccinated using old vial from 03/08/2021) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported by the reported No treatment information was provided   This case was linked to MOD-2021-208074, MOD-2021-258552, MOD-2021-258587, MOD-2021-258599, MOD-2021-258615, MOD-2021-258632, MOD-2021-258644, MOD-2021-258660, MOD-2021-258672, MOD-2021-258682, MOD-2021-258689, MOD-2021-258691, MOD-2021-258693, MOD-2021-258697, MOD-2021-258699, MOD-2021-258700, MOD-2021-258702, MOD-2021-258703, MOD-2021-258704, MOD-2021-258706, MOD-2021-208074 (Patient Link).
congested; coughing; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (congested) and COUGH (coughing) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NASAL CONGESTION (congested) and COUGH (coughing). At the time of the report, NASAL CONGESTION (congested) and COUGH (coughing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications details were not reported by the reporter. Treatment details was not reported by the reporter.   Reporter did not allow further contact
Client became pale and was perspiring.  Client was placed in a wheelchair by EMS and then taken to an area in the reconstitution area to be assessed.  Patient was placed in supine with legs elevated and given water.  Patient color improved stopped perspiring.  Patient was asked if he wished to be transported to a hospital  and he stated he was okay to go home.  Patient walked out at his end of observation time 11:13 am.
A male patient, medical history not reported developed chest pain considered moderate in severity, 10 days after he received an injection of ACAM2000, SP Biologics Co., (lot number, route, site and side not reported) on 24 March 2014 and concomitantly an injection of Typhoid Vaccine, manufacturer not reported, (lot number, route, site and side not reported) on 24 March 2014. On 03 April 2014, 10 days post vaccination, the subject reported at visit 2, that he experienced two episodes of chest pain, first lasting several hours waking him from sleep and the following episode lasting about 45 minutes to an hour. Both improved with hot showers. He did not take any medications or seek medication attention. An EKG and Troponin I (<0.10 ng/mL) were normal on 08 April 2014. The subject was referred appropriately for care. The subject recovered on 05 April 2014. According to the reporter the event of chest pain was considered other important medical event and possibly related to the trial product. Documents held by sender: None.
We received the childrens vaccine on 10/6/2023 when I was not at work.  I was not aware that we received the childrens vaccine.  In an effort to do the most efficient thing for our store due to being behind on all the rx ques I thought using the single dose vials would be most efficient when the most staff was one hand to use them up.  It was discovered when using the NDC for another patient that this was the children's dose due to the rx adjudicating. the patient returned and received the adult dosage according the CDC recommendations.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: Patient laid on floor was given water sat up rested i chair for 20 minutes and was fine. Has had history similar reaction to shots
dizzy spells; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 57 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 05Mar2021 (Batch/Lot number: unknown) at the age of 57 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Cancer in lymph nodes", start date: 2015 (unspecified if ongoing), notes: She had cancer in her Lymph nodes, but she is in remission.; "swollen lymph nodes" (unspecified if ongoing), notes: She has had cancer and swollen lymph nodes from that; "lymph nodes removed" (unspecified if ongoing), notes: The took 8 of the lymph nodes out.; "high blood pressure" (ongoing), notes: about 7 years ago; "Schizophrenia", start date: 1989 (ongoing); "Asthma" (ongoing), notes: 3 years ago. There were no concomitant medications. The following information was reported: DIZZINESS (non-serious) with onset 07Mar2021, outcome "not recovered", described as "dizzy spells". Relevant laboratory tests and procedures are available in the appropriate section.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
A few days after receiving her second shot some of her hair fell out and that now her hair has a different texture; A few days after receiving her second shot some of her hair fell out and that now her hair has a different texture; This is a spontaneous report from a contactable reporter (consumer or other non-HCP).   An adolescent female patient (unknown if pregnant) received bnt162b2 (BNT162B2) (Lot number: unknown) as dose 2, single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot Number: UNKNOWN; Route of Administration: Unspecified), for COVID-19 immunisation.  The following information was reported: ALOPECIA (non-serious), HAIR TEXTURE ABNORMAL (non-serious) all with, outcome "unknown", and all described as "A few days after receiving her second shot some of her hair fell out and that now her hair has a different texture".   Additional Information: The patient is 14-15 years of age. It was unknown whether any therapeutic measures were taken as a result of the events. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Employee received the COVID vaccine on 12/21/2020. Employee reports her symptoms started on 12/30/2020. Employee states she cannot turn key in door or use right arm and hand normally. Employee reports parasthesias including slight numbness and tingling. Employee reports pain that is in the back of her shoulder that is rated as 2-3/10. Employee states all of her symptoms have been the same since 12/30 and have not worsened and no new symptoms had started.
Tdap given to a 34yr old preg female site: LD on January 8, 2008.  Pt informed of incident and told to inform her Doctor.
Rec'd vaccines 8/17/15 at WCE. C/O (Lt) arm with redness and warmth on exam at 8/19/15 O.V. -> 2.5 x 3" area erythema (Lt) shoulder with mild warmth and tenderness. No induration; no fever. TX with PRN ibuprofen/warm compress.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. The patient's medical history was not reported. On 19-APR-2016, the patient was vaccinated with an expired dose of VARIVAX (Merck) lot # K005426, expiration date reported as 15-APR-2016 (dose, route and site of administration were not reported). Concomitant medication were not reported. No symptoms were reported. Additional information has been requested.